Published online Jun 6, 2022. doi: 10.12998/wjcc.v10.i16.5495
Peer-review started: December 21, 2021
First decision: January 25, 2022
Revised: January 30, 2022
Accepted: April 29, 2022
Article in press: April 29, 2022
Published online: June 6, 2022
Processing time: 162 Days and 19.6 Hours
Congenital tuberculosis (TB), tuberculous meningitis, and situs inversus totalis are rare diseases. We here report a patient who simultaneously suffered from these three rare diseases. There is currently no such report in the literature. Congenital TB is easily misdiagnosed and has a high case fatality rate. Timely anti-TB treatment is required.
A 19-day-old male newborn was admitted to hospital due to a fever for 6 h. His blood tests and chest X-rays suggested infection, and he was initially considered to have neonatal pneumonia and sepsis. He did not respond to conventional anti-infective treatment. Finally, Mycobacterium tuberculosis was found in sputum lavage fluid on the 10th day after admission. In addition, the mother's tuberculin skin test was positive, with an induration of 22 mm, and her pelvic computed tomography scan suggested the possibility of tuberculous pelvic inflammatory disease. The child was diagnosed with congenital TB and immediately managed with anti-TB therapy and symptomatic supportive treatment. However, the infant's condition gradually worsened and he developed severe tuberculous pneumonia and tuberculous meningitis, and eventually died of respiratory failure.
If conventional anti-infective treatment is ineffective in neonatal pneumonia, anti-TB treatment should be considered.
Core Tip: Congenital tuberculosis (TB) is rare in the clinic, and early diagnosis is challenging. The disease develops rapidly, and the mortality rate is exceptionally high. In the present case, the infant's condition worsened due to delays in diagnosis and anti-TB treatment, and he developed severe tuberculous pneumonia and tuberculous meningitis, and eventually died of respiratory failure. Early screening of TB infection and anti-TB treatment are essential to reduce mortality and improve the prognosis in children who do not respond to conventional anti-infective therapy.